(Rac)-Moxifloxacin_product_DataBase

Bioactivity

(Rac)-Moxifloxacin ((Rac)-BAY 12-8039 free base) is the isoform of Moxifloxacin Hydrochloride (HY-66011), which is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].

Invitro

通过使用感染李斯特菌的骨髓源性小鼠巨噬细胞模型进行时间杀伤曲线和细胞内生长抑制实验，比较了盐酸莫西沙星 (BAY 12-8039) 和阿莫西林的体外活性。单核细胞增多症 EGDe。莫西沙星作用更加迅速，在前3小时内开始发挥作用，并在培养24小时内实现肉汤完全灭菌。莫西沙星似乎对巨噬细胞裂解具有保护作用，因为许多细胞在孵育 24 小时后仍然存活[3]。 0 --> (Rac)-Moxifloxacin 相关抗体:

In Vivo

Moxifloxacin (BAY 12-8039；12 mg/kg；静脉注射；每天一次至三次；持续 7 天；白色雄性 Wistar 大鼠) 每 8 小时治疗一次可延长生存期。细菌攻击后 30 小时的组织培养显示，与盐水处理的动物相比，莫西沙星处理的脾脏和肺部细菌过度生长明显减少，并且没有毒性[4]。

Name

(Rac)-Moxifloxacin

CAS

354812-41-2

Formula

C21H24FN3O4

Molar Mass

401.43

Appearance

Powder

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Culley CM, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm. 2001 Mar 1;58(5):379-88. [2]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39. [3]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. [4]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.

PeptideDB

(Rac)-Moxifloxacin

CAS: 354812-41-2 F: C21H24FN3O4 W: 401.43